|
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study |
|
|
|
Titel: |
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study |
Auteur: |
Daniele, Gennaro Raspagliesi, Francesco Scambia, Giovanni Pisano, Carmela Colombo, Nicoletta Frezzini, Simona Tognon, Germana Artioli, Grazia Gadducci, Angiolo Lauria, Rossella Ferrero, Annamaria Cinieri, Saverio De Censi, Andrea Breda, Enrico Scollo, Paolo De Giorgi, Ugo Lissoni, Andrea Alberto Katsaros, Dionyssios Lorusso, Domenica Salutari, Vanda Cecere, Sabrina Chiara Zaccarelli, Eleonora Nardin, Margherita Bogani, Giorgio Distefano, Mariagrazia Greggi, Stefano Piccirillo, Maria Carmela Fossati, Roldano Giannone, Gaia Arenare, Laura Gallo, Ciro Perrone, Francesco Pignata, Sandro |
Verschenen in: |
International journal of gynecological cancer |
Paginering: |
Jaargang 31 () nr. 6 pagina's 875-882 |
Jaar: |
2021 |
Inhoud: |
|
Uitgever: |
IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ. |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|